TY - JOUR
T1 - Current Advances in the Prevention, Risk, and Management of Infection in Patients Receiving Biologic Therapy for Dermatologic Disorders
AU - Kosche, Cory A.
AU - Ali, Yasmeen
AU - Figueiredo, Anna C.
AU - West, Dennis P.
AU - Nardone, Beatrice
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/9/15
Y1 - 2019/9/15
N2 - Purpose of Review: Biologic agents such as adalimumab, etanercept, golimumab, certolizumab, ustekinumab, brodalumab, secukinumab, ixekizumab, dupilumab, alefacept, rituximab, omalizumab, tildrakizumab, and guselkumab are now indicated in the treatment of dermatologic disorders. This review reports on current prevention, risk, and management of infection in patients receiving biologic therapy for dermatologic disorders. Recent Findings: Although risk of infection in patients receiving biologic agents for management of a dermatologic disorder is well-known, it appears to continue to be a low risk. However, optimal prevention and management of some infection risks remain an unmet need. Summary: Although the overall risk for infection during biologic therapy for dermatologic disorders appears to remain low, there remains concern about the level of risk for reactivation of tuberculosis, as well as hepatitis B and C, and the risk for other, often uncommon, serious infection remains unknown. Continued pharmacovigilance serves to mitigate risk as well as promote optimal management of dermatologic disorders with biologic agents.
AB - Purpose of Review: Biologic agents such as adalimumab, etanercept, golimumab, certolizumab, ustekinumab, brodalumab, secukinumab, ixekizumab, dupilumab, alefacept, rituximab, omalizumab, tildrakizumab, and guselkumab are now indicated in the treatment of dermatologic disorders. This review reports on current prevention, risk, and management of infection in patients receiving biologic therapy for dermatologic disorders. Recent Findings: Although risk of infection in patients receiving biologic agents for management of a dermatologic disorder is well-known, it appears to continue to be a low risk. However, optimal prevention and management of some infection risks remain an unmet need. Summary: Although the overall risk for infection during biologic therapy for dermatologic disorders appears to remain low, there remains concern about the level of risk for reactivation of tuberculosis, as well as hepatitis B and C, and the risk for other, often uncommon, serious infection remains unknown. Continued pharmacovigilance serves to mitigate risk as well as promote optimal management of dermatologic disorders with biologic agents.
KW - Adverse events
KW - Biologic agents
KW - Dermatologic disorders
KW - Infections
KW - Infectious disease
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85069721095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069721095&partnerID=8YFLogxK
U2 - 10.1007/s13671-019-0262-0
DO - 10.1007/s13671-019-0262-0
M3 - Review article
AN - SCOPUS:85069721095
SN - 2162-4933
VL - 8
SP - 141
EP - 148
JO - Current Dermatology Reports
JF - Current Dermatology Reports
IS - 3
ER -
